Polygenic Risk Score to Predict Weight Loss Intervention in Children With Obesity
-
- STATUS
- Recruiting
-
- End date
- Jul 31, 2025
-
- participants needed
- 300
-
- sponsor
- Far Eastern Memorial Hospital
Summary
Children with obesity are prone to suffering from metabolic diseases, which undoubtedly increases the burden of public health. Since obesity is a multiple gene disease, a comprehensive approach using polygenic risk scores (PRS), rather than individual genetic variant, may be a more appropriate method. The aim of the study was to establish a polygenic risk score model to assess differences to assess differences in weight loss treatment outcomes.
Description
We hypothesize that obesity gene variants can predict the efficacy of weight loss intervention in obese children. The aim of the study was to establish a polygenic risk score model to assess differences to assess differences in weight loss treatment outcomes. We will also analyze whether these gene variants have an effect on obesity comorbidities (hypertension, hyperlipidemia, non-alcoholic fatty liver disease, type 2 diabetes, obstructive sleep apnea, polycystic ovary syndrome, etc.). For patients with non-simple obesity, we will collect their complete family history, and perform whole exome sequencing to identify possible rare disease-causing genes.
The experimental design is as follows:
Obese children and adolescent subjects will undergo a 6-month weight loss intervention program and be followed for 12-18 months. We will analyze obesity and fatty liver-related genes in these adolescents using next-generation gene sequencing and/or gene chips, perform polygenic risk score analysis, and use an additive model to total the number of variant loci, weighted by effect size. Whole exome gene sequencing refers to the human DNA map (hg19), and Sanger sequencing is used to confirm the correctness of the variant site.
Details
| Condition | Obesity, Children |
|---|---|
| Clinical Study Identifier | NCT05466097 |
| Sponsor | Far Eastern Memorial Hospital |
| Last Modified on | 4 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer